Abstract
Purpose
The aim of our study was to evaluate and compare the expression of different immunohistochemical markers in Bladder Carcinomas (BC) in patients with Neurogenic Bladder (NB) and Urinary Schistosomiasis (US) infection.
Materials and methods
We collected tissue samples from patients with Neurogenic Bladder and Bladder Carcinoma (NBC Group) and from patients with Urinary Schistosomiasis infection and Bladder Carcinoma (SBC Group). We compared to these two groups to control samples from resection from patients with Urinary Schistosomiasis without Bladder Carcinoma (US Group); we also investigate patients’ characteristics according to urothelial transitional cell carcinoma (TCC), and squamous cell carcinoma (SCC) histopathological differentiation. The expression of markers in all groups (CK7, CK14, CK20, FoxP3, GATA3, STAG2, CD3, CD8, Ki67, and P53) was analyzed using immunohistochemistry of tissue micro-array sections (TMA).
Results
Overall, 136 patients were included in the study (n = 72 in the NBC group, n = 33 in the SBC group, and n = 31 in the US group). In the TCC subgroup, the expression of CK7, CK14, CK20, and Ki67 was significantly higher compared to US controls (p 0.002; p < 0.001; p 0.036; p < 0.001). In the SCC subgroup, the expression of CK7, CK14, and CK20 was significantly higher compared to US controls (p 0.007; p < 0.001; p 0.005). Both in TCC and SCC subgroups, no difference in the expression of any tested markers was found comparing NBC and SBC groups. In US group, a significant higher expression of STAG2 was found compared to SCC subgroup (p 0.005).
Conclusion
Based on our results, the profile of immunohistochemical biomarkers’ expression in both NBC and SBC groups is similar.
Similar content being viewed by others
Abbreviations
- BC:
-
Bladder carcinoma
- NB:
-
Neurogenic bladder
- US:
-
Urinary schistosomiasis
- NBC:
-
Bladder carcinoma in neurogenic bladder patients
- SBC:
-
Bladder carcinoma in patients with urinary schistosomiasis infection
- TCC:
-
Transitional cell carcinoma
- SCC:
-
Squamous cell carcinoma
- PCC:
-
Papillary cell carcinoma
- TURB:
-
Transurethral resection of the bladder
References
Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin. https://doi.org/10.3322/caac.21654
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. https://doi.org/10.3322/caac.21660
Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A (2020) Epidemiology of bladder cancer. Med Sci 8:1–12
Berry A, Iriart X, Fillaux J, Magnaval JF (2017) Schistosomose urogénitale et cancer. Bull Soc Pathol Exot. https://doi.org/10.1007/s13149-017-0547-4
Ismail S, Karsenty G, Chartier-Kastler E, Cussenot O, Compérat E, Rouprêt M, Phé V (2018) Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: a systematic review. Neurourol Urodyn 37:1386–1395
Zaghloul MS, Gouda I (2012) Schistosomiasis and bladder cancer: Similarities and differences from urothelial cancer. Expert Rev Anticancer Ther 12:753–763
Arslan B, Bozkurt IH, Yonguc T, Vardar E, Degirmenci T, Kozacioglu Z, Gunlusoy B, Minareci S (2015) Clinical features and outcomes of nontransitional cell carcinomas of the urinary bladder: analysis of 125 cases. Urol Ann. https://doi.org/10.4103/0974-7796.150533
Park JH, Moon KC (2018) Tumor, nodes, metastases (TNM) classification system for bladder cancer. Bladder Cancer. https://doi.org/10.1016/B978-0-12-809939-1.00012-6
Phé V, Rouprêt M, Cussenot O, Chartier-Kastler E, Gamé X, Compérat E (2015) Forkhead box protein P3 (Foxp3) expression serves as an early chronic inflammation marker of squamous cell differentiation and aggressive pathology of urothelial carcinomas in neurological patients. BJU Int 115:28–32
Abdulamir AS, Hafidh RR, Kadhim HS, Abubakar F (2009) Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors. J Exp Clin Cancer Res. https://doi.org/10.1186/1756-9966-28-27
Hassan HE, Mohamed AAB, Bakhiet AO, Ahmed HG (2013) Immunohistochemical expression of COX2 and iNOS in bladder cancer and its association with urinary schistosomiasis among Sudanese patients. Infect Agents Cancer. https://doi.org/10.1186/1750-9378-8-9
Badawy AA, El-Hindawi A, Hammam O, Moussa M, Helal NS, Kamel A (2017) Expression of epidermal growth factor receptor and transforming growth factor alpha in cancer bladder: Schistosomal and non-schistosomal. Curr Urol 9:192–201
Gouveia MJ, Santos J, Brindley PJ, Rinaldi G, Lopes C, Santos LL, da Costa JMC, Vale N (2015) Estrogen-like metabolites and DNA-adducts in urogenital schistosomiasis-associated bladder cancer. Cancer Lett 359:226–232
El-Aal AAA, Emran AM, Al-Antably AS, el Saftawy EA, Bayoumy IR, Hassan NS, Badawi M (2015) Immunohistochemical pattern of T lymphocytes population within bilharzial-associated bladder neoplasm microenvironment. Int J Immunopathol Pharmacol 28:209–217
Bernardo C, Cunha MC, Santos JH, da Costa JMC, Brindley PJ, Lopes C, Amado F, Ferreira R, Vitorino R, Santos LL (2016) Insight into the molecular basis of schistosoma haematobium-induced bladder cancer through urine proteomics. Tumor Biology 37:11279–11287
Choi W, Porten S, Kim S et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. https://doi.org/10.1016/j.ccr.2014.01.009
Ishida K, Hsieh MH (2018) Understanding urogenital schistosomiasis-related bladder cancer: an update. Front Med. https://doi.org/10.3389/fmed.2018.00223
Koonrungsesomboon N, Wadagni AC, Mbanefo EC (2015) Molecular markers and Schistosoma-associated bladder carcinoma: a systematic review and meta-analysis. Cancer Epidemiol 39:487–496
Youssef RF, Shariat SF, Kapur P et al (2011) Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder. Hum Pathol. https://doi.org/10.1016/j.humpath.2010.07.012
Solomon DA, Kim JS, Bondaruk J et al (2013) Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet. https://doi.org/10.1038/ng.2800
Lelo A, Prip F, Harris BT et al (2018) STAG2 is a biomarker for prediction of recurrence and progression in papillary non–muscle-invasive bladder cancer. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-17-3244
Zaghloul MS, Zaghloul TM, Bishr MK, Baumann BC (2020) Urinary schistosomiasis and the associated bladder cancer: update. J Egypt Natl Canc Inst. https://doi.org/10.1186/s43046-020-00055-z
Sui X, Lei L, Chen L, Xie T, Li X (2017) Inflammatory microenvironment in the initiation and progression of bladder cancer. Oncotarget. https://doi.org/10.18632/oncotarget.21565
Schlager TA, Legallo R, Innes D, Hendley JO, Peters CA (2011) B cell infiltration and lymphonodular hyperplasia in bladder submucosa of patients with persistent bacteriuria and recurrent urinary tract infections. J Urol. https://doi.org/10.1016/j.juro.2011.07.114
Sharma P, Shen Y, Wen S et al (2007) CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.0611618104
Yu A, Mansure JJ, Solanki S, Siemens DR, Koti M, Dias ABT, Burnier MM, Brimo F, Kassouf W (2018) Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy. PLoS One. https://doi.org/10.1371/journal.pone.0205746
Krpina K, Babarović E, Jonjić N (2015) Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma. Virchows Arch. https://doi.org/10.1007/s00428-015-1808-6
Acknowledgements
We would like to thank for the help in lab work Géraldine Cancel-Tassin. We would like to thank Dr. Anne Cremades, Dr. Céline Bazille, Pr Pierre Gosset, Dr. Laurent Daniel, Dr. Philippe Rouvier, Dr. Anne Durlach, Dr. Nathalie Rioux Leclercq, Dr. Sarah Pericart, Dr. Carla Fernandez, Dr. Aurélien Rock, Dr. Grégoire Léon, Dr. François-Régis Desfemmes, Dr. Benoît Peyronnet, Dr. Jérémy Fallot, Dr. Priscilla Léon, Dr. Emmanuel Rolland, Dr. Eric Huyghe, Dr. Xavier Gamé, Dr. Marie-Aimée Perrouin-Verbe, Dr. Jacques Wodey, Dr. Grégoire Capon, and Dr. Alain Ruffionfor for their participation in this project. We also thank the French Association of Urology (Association Française d’Urologie-AFU) and the French-speaking Neuro-Urology study group for supporting this work.
Funding
None.
Author information
Authors and Affiliations
Contributions
FC: research design, acquisition, analysis and interpretation of data; draft the paper, approved the submitted and final versions. FM: research design, acquisition of data; revised the paper critically; approved the submitted and final versions. OC: research design; revised the paper critically; approved the submitted and final versions. HA: pathological analysis of specimen; revised the paper critically; approved the submitted and final versions. EC: pathological analysis of specimen; revised the paper critically; approved the submitted and final versions. VP: research design, interpretation of data; revised the paper critically; approved the submitted and final versions.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no competing interests.
Human participants
The research involved human tissue collected for diagnostic purposes and conserved in the Pathology Lab in Tenon Hospital, Sorbonne University, Paris France.
Informed consent
The collection and use of all bladder tissue samples was performed after the approval of the local ethics committee, informed consent, and in accordance with all relevant laws, regulations, and codes of practice in France.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Cancrini, F., Michel, F., Cussenot, O. et al. Bladder carcinomas in patients with neurogenic bladder and urinary schistosomiasis: are they the same tumors?. World J Urol 40, 1949–1959 (2022). https://doi.org/10.1007/s00345-022-03941-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-022-03941-4